var data={"title":"Lenvatinib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lenvatinib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/765751?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lenvatinib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lenvatinib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27277214\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lenvima 10 MG Daily Dose;</li>\n      <li>Lenvima 14 MG Daily Dose;</li>\n      <li>Lenvima 18 MG Daily Dose;</li>\n      <li>Lenvima 20 MG Daily Dose;</li>\n      <li>Lenvima 24 MG Daily Dose;</li>\n      <li>Lenvima 8 MG Daily Dose</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49242805\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lenvima</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27157980\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Tyrosine Kinase Inhibitor;</li>\n      <li>\n        Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27378082\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Lenvatinib is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell carcinoma, advanced:</b> Oral: 18 mg once daily (in combination with everolimus), continue until disease progression or unacceptable toxicity (Motzer 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid cancer, differentiated:</b> Oral: 24 mg once daily until disease progression or unacceptable toxicity (Schlumberger 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatocellular carcinoma, advanced (off-label use):</b> Oral: 12 mg once daily (patients &ge;60 kg) or 8 mg once daily (patients &lt;60 kg) (Cheng 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses:</i> Do not take a missed dose within 12 hours of the next dose (if within 12 hours, skip the missed dose and return to regular administration time).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27378083\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27378084\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Preexisting renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Renal cell cancer, advanced:</i> 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Thyroid cancer, differentiated:</i> 14 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Lenvatinib is not expected to be dialyzable (due to high protein binding).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal toxicity during treatment: </b>Interrupt therapy or discontinue if grade 3 or 4 renal failure or impairment develops. Consider resuming at a reduced dose if resolves to &le; grade 1 or baseline (depending on severity and persistence of toxicity).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27378085\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Preexisting hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Renal cell cancer, advanced:</i> 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Thyroid cancer, differentiated:</i> 14 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatotoxicity during treatment:</b> Interrupt therapy if grade 3 or 4 hepatotoxicity develops. When improved to &le; grade 1 or baseline, may either resume at a reduced dose or discontinue, depending on severity and persistence of toxicity. Discontinue for hepatic failure; do not resume.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27378086\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Recommended dose modifications for persistent and intolerable grade 2 or grade 3 adverse reactions or grade 4 laboratory abnormalities:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Renal cell cancer, advanced:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>First occurrence:</i> Interrupt therapy until resolved to &le; grade 1 or baseline, then resume dosing at 14 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Second occurrence (same or different toxicity):</i> Interrupt therapy until resolved to &le; grade 1 or baseline, then resume dosing at 10 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Third occurrence (same or different toxicity):</i> Interrupt therapy until resolved to &le; grade 1 or baseline, then resume dosing at 8 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> For toxicities related only to everolimus, reduce frequency to every other day or interrupt or discontinue everolimus (refer to everolimus monograph for dosage adjustment for toxicity). For toxicities related to both lenvatinib and everolimus, first reduce lenvatinib, and then everolimus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Thyroid cancer, differentiated:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>First occurrence:</i> Interrupt therapy until resolved to &le; grade 1 or baseline, then resume dosing at 20 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Second occurrence (same or different toxicity):</i> Interrupt therapy until resolved to &le; grade 1 or baseline, then resume dosing at 14 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Third occurrence (same or different toxicity):</i> Interrupt therapy until resolved to &le; grade 1 or baseline, then resume dosing at 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Arterial thrombotic event:</b> Discontinue therapy; do not resume.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiac:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Cardiac dysfunction:</i> Temporarily interrupt therapy for a grade 3 event until improved to &le; grade 1 or baseline; depending on severity and persistence of toxicity, may either resume therapy at a reduced dose or discontinue treatment. Discontinue for a grade 4 event; do not resume.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hypertension:</i> Monitor blood pressure prior to and throughout therapy; initiate or adjust antihypertensive medication to control blood pressure. Temporarily interrupt therapy for grade 3 hypertension that persists despite optimal medical management. When hypertension is &le; grade 2, resume therapy at a reduced dose. Discontinue therapy for life-threatening hypertension; do not resume.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>QT prolongation:</i> Temporarily interrupt therapy for &ge; grade 3 QT prolongation (&gt;500 msec). When improved to &le; grade 1 (&lt;480 msec) or baseline, resume therapy at a reduced dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastrointestinal toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nausea, vomiting, or diarrhea:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3: Initiate prompt medical management prior to interrupting therapy (or reducing dose) until resolves to &le; grade 1 or baseline; then resume (for diarrhea, resume at a reduced dose).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 4 vomiting or diarrhea despite optimal medical management: Discontinue therapy; do not resume.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Perforation (any grade) or fistula formation (grade 3 or 4; life-threatening):</i> Discontinue therapy; do not resume.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemorrhage: </b>Temporarily interrupt therapy for a grade 3 event until improved to &le; grade 1; depending on severity and persistence of toxicity, may either resume therapy at a reduced dose or discontinue treatment. Discontinue for a grade 4 event; do not resume.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypocalcemia:</b> Administer calcium replacement therapy as necessary; may require treatment interruption or dose reduction depending on the severity, presence of ECG changes, and persistence of hypocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nephrotic syndrome:</b> Discontinue therapy; do not resume.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Proteinuria:</b> Temporarily interrupt therapy for &ge;2 g proteinuria/24 hours; resume therapy at a reduced dose when improved to &lt;2 g proteinuria/24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversible posterior leukoencephalopathy syndrome (RPLS):</b> Interrupt or discontinue therapy until fully resolved; consider resuming at a reduced dose if resolves to &le; grade 1, depending on severity and persistence of neurologic symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27277215\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Therapy Pack, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lenvima 10 MG Daily Dose: 10 mg (30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lenvima 14 MG Daily Dose: 10 mg &amp; 4 mg (60 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lenvima 18 MG Daily Dose: 10 mg &amp; 2x4 mg (15 ea, 90 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lenvima 20 MG Daily Dose: 2x10 mg (60 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lenvima 24 MG Daily Dose: 2x10 mg &amp; 4 mg (90 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lenvima 8 MG Daily Dose: 2x4 mg (10 ea, 60 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27277213\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27339507\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Each Lenvima Therapy Pack contains a 30 day supply of dosage units</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27377699\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Lenvatinib is available only through specialty pharmacies. For further information on patient assistance, product availability, and prescribing instructions, please refer to the following website: http://www.lenvima.com/hcp/pharmacy-financial-options</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27378092\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenvatinib is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer orally at the same time each day (administer lenvatinib and everolimus at the same time each day when used for the treatment of renal cell cancer). May be administered without regards to meals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules should be swallowed whole, however, if unable to swallow whole, the capsules may be dissolved in a small glass of liquid. Measure 15 mL of water or apple juice into a glass; add whole capsule and leave in liquid for at least 10 minutes, then stir for at least 3 minutes. Administer liquid, then add 15 mL of additional water or apple juice to glass, swirl a few times and then swallow additional liquid.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132642\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Lenvatinib may be teratogenic, cause reproductive toxicity, and has a structural/toxicity profile similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27157982\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal cell carcinoma, advanced:</b> Treatment of advanced renal cell carcinoma (in combination with everolimus) following one prior anti-angiogenic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thyroid cancer, differentiated:</b> Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50786809\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hepatocellular carcinoma (advanced)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27377697\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lenvatinib may be confused with cabozantinib, lapatinib, vandetanib</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lenvima may be confused with Lynparza</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27386862\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (73%), peripheral edema (21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (67%), headache (38%), voice disorder (31%), mouth pain (25%), dizziness (15%), insomnia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Palmar-plantar erythrodysesthesia (32%), skin rash (21%), alopecia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased thyroid stimulating hormone level (57%), weight loss (51%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (67%), decreased appetite (54%), nausea (47%), stomatitis (41%), vomiting (36%), abdominal pain (31%), constipation (29%), dysgeusia (18%), xerostomia (17%), dyspepsia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Proteinuria (34%), urinary tract infection (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (35%; grades &ge;3: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (&le;62%), myalgia (&le;62%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (24%), epistaxis (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (9%), prolonged Q-T interval on ECG (9%), thromboembolic complications (5%), pulmonary embolism (3%), reduced ejection fraction (2%; ejection fraction reduced by &gt;20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperkeratosis (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (9%), hypocalcemia (grades 3/4: 9%), hypokalemia (grades 3/4: 6%), hypercalcemia (&gt;5%), hypercholesterolemia (&gt;5%), hyperkalemia (&gt;5%), hypoalbuminemia (&gt;5%), hypoglycemia (&gt;5%), hypomagnesemia (&gt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Infection of mouth (10%), increased serum amylase (&gt;5%), increased serum lipase (grades 3/4: 4%), gastrointestinal fistula (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased platelet count (grades 3/4: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (&gt;5%), increased serum alkaline phosphatase (&gt;5%), increased serum AST (grades 3 or higher: 5%), increased serum ALT (grades 3 or higher: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (grades 3/4: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pulmonary edema (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Pancreatitis, reversible posterior leukoencephalopathy syndrome, tumor hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27157983\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canadian labeling: Hypersensitivity to lenvatinib or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27377922\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac effects: Hypertension, including grade 3 and 4 toxicity, occurred in patients treated with lenvatinib in clinical trials; the median time to onset of new or worsening hypertension was 16 to 35 days. Blood pressure should be controlled prior to initiating therapy; monitor frequently throughout treatment. Other cardiac events, such as decreased left or right ventricular function, decreased ejection fraction (EF), cardiac failure, or pulmonary edema, were also reported, including grades 2, 3, and 4 events. In patients with thyroid cancer, decreased ejection fraction was the most commonly reported of these events; some patients experienced greater than 20% EF reduction. Monitor for signs/symptoms of cardiac decompensation. QT/QTc prolongation was also observed in lenvatinib-treated patients, including prolongation &gt;500 msec and increases &gt;60 msec from baseline. Monitor and correct electrolyte abnormalities in all patients; obtain electrocardiograms in patients with congenital long QT syndrome, heart failure, bradyarrhythmias, or in those on concomitant medications known to prolong the QT interval. Cardiac effects may require therapy interruption, dosage reduction, or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endocrine effects: Lenvatinib impairs exogenous thyroid suppression. In patients with differentiated thyroid cancer and a normal thyroid stimulating hormone (TSH) level at baseline, TSH elevations were observed in over half of lenvatinib-treated patients. Grades 1 and 2 hypothyroidism occurred in renal cell cancer patients receiving lenvatinib and everolimus; TSH elevations occurred in over half of in patients with a normal or low TSH at baseline. Monitor TSH levels at baseline and at least monthly; adjust thyroid hormone therapy or manage hypothyroidism as clinically necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal perforation/fistula: Gastrointestinal perforation, fistula formation, or abscess were reported in a small percentage of patients in clinical trials. Discontinue use in patients who develop perforation or life-threatening fistula.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Lenvatinib is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017). Nausea, vomiting, and diarrhea were commonly observed. Initiate appropriate management prior to therapy interruption or dosage reduction; initiate active management of diarrhea and other gastrointestinal symptoms for grade 1 or higher events. Monitor closely for dehydration; dehydration or hypovolemia due to diarrhea and vomiting are risk factors for renal toxicity. Diarrhea may require treatment interruption, dose reduction, and or discontinuation. The incidence of diarrhea is higher in when lenvatinib is used in combination with everolimus; recurrent diarrhea occurred despite dose reduction. Diarrhea was the most common reason for dose reduction or treatment interruption in patients with renal cell cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemorrhage: Hemorrhagic events (most frequently epistaxis) occurred in over one-third of lenvatinib-treated patients. Serious tumor-related bleeding events (including cases of fatal hemorrhage) have been observed in clinical trials and postmarketing surveillance. Serious and fatal carotid artery hemorrhages were reported more frequently in patients with anaplastic thyroid carcinoma (ATC) than with other tumor types. Safety and efficacy of lenvatinib have not been established in the treatment of ATC. Consider the risk of hemorrhage associated with tumor infiltration/invasion of major blood vessels. Monitor for bleeding; may require therapy interruption, dosage reduction, or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Elevations in transaminases (including grade 3 or greater events) were observed. There have been case reports of hepatic failure (some fatal) and acute hepatitis with single-agent lenvatinib. Monitor liver function tests at baseline and throughout therapy. May require therapy interruption, dosage reduction, or discontinuation. If hepatic failure occurs, discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: An increased incidence of hypocalcemia (including grade 3 events) was observed in lenvatinib-treated patients compared to the control group in clinical trials. Calcium replacement therapy and dosage interruption or reduction generally corrected hypocalcemia. Monitor serum calcium levels at least monthly; replace calcium as necessary. May require therapy interruption or dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Palmar-plantar erythrodysesthesia: Palmar-plantar erythrodysesthesia (usually grades 1 to 2) was observed in nearly one-third of patients receiving lenvatinib.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: Proteinuria (including grade 3 toxicity) was commonly observed. Monitor for proteinuria at baseline and periodically throughout therapy. If urine dipstick for proteinuria is 2+, obtain a 24-hour urine protein. Withhold treatment for proteinuria &ge;2 g/24 hours; resume at a reduced dose when proteinuria is &lt;2 g/24 hours. Discontinue for nephrotic syndrome. Renal impairment may also occur (may be grade 3 or higher); a primary risk factor for severe renal impairment is dehydration or hypovolemia due to diarrhea and vomiting. Monitor renal function throughout treatment; may require therapy interruption, dosage reduction, or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reversible posterior leukoencephalopathy syndrome: Reversible posterior leukoencephalopathy syndrome (RPLS) has occurred (rarely). If RPLS diagnosis is confirmed through MRI, interrupt treatment until fully resolved. Therapy may resume at a reduced dose or be discontinued, depending on the severity and persistence of neurologic symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Arterial thromboembolic events, including grade 3 or greater events, have been reported. Discontinue treatment if arterial thrombosis occurs; the safety of resuming therapy after such an event has not been established. Lenvatinib has not been studied in patients who have had an arterial thromboembolic event within the preceding 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27164162\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BSEP/ABCB11, OAT1, OAT3, OATP1B1/SLCO1B1, OCT1, OCT2, UGT1A1, UGT1A4</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27164159\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=99962&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irinotecan Products: UGT1A1 Inhibitors may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be increased. UGT1A1 Inhibitors may increase the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27377702\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Based on the mechanism of action, lenvatinib may cause fetal harm if administered in pregnancy. Females of reproductive potential should use effective contraception during lenvatinib treatment and for at least 2 weeks after completion of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27377704\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if lenvatinib is present in breast milk. The manufacturer recommends that breastfeeding be discontinued during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27378102\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests (at baseline, every 2 weeks for 2 months, and at least monthly thereafter); renal function; electrolytes; serum calcium at least monthly; TSH levels at baseline and monthly or as clinically indicated; monitor for proteinuria at baseline and periodically during treatment (urine dipstick; if 2+ then 24-hour urine protein); monitor blood pressure after 1 week, then every 2 weeks for 2 months, and at least monthly thereafter; electrocardiogram in select patients; monitor for signs/symptoms of cardiac decompensation, arterial thrombosis, reversible posterior leukoencephalopathy syndrome, GI perforation/fistula, hemorrhagic events, GI toxicity, and dehydration. Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27378026\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Lenvatinib is a multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, platelet derived growth factor receptor alpha (PDGFR&alpha;), KIT, and RET. Inhibition of these receptor tyrosine kinases leads to decreased tumor growth and slowing of cancer progression. Combining lenvatinib with everolimus has demonstrated increased antiangiogenic and antitumor activity  by decreasing human endothelial cell proliferation, tube formation, and VEGF signaling (in vitro) compared to either drug alone.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27378028\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 98% to 99%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily enzymatic through CYP3A and aldehyde oxidase; nonenzymatic metabolism also occurs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~28 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~64%); urine (~25%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27658121\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule Therapy Pack</b> (Lenvima 10 MG Daily Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (5): $3,194.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule Therapy Pack</b> (Lenvima 14 MG Daily Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 &amp; 4 mg (10): $3,194.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule Therapy Pack</b> (Lenvima 18 MG Daily Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 &amp; 4 (2) mg (15): $3,394.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule Therapy Pack</b> (Lenvima 20 MG Daily Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 (2) mg (10): $3,394.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule Therapy Pack</b> (Lenvima 24 MG Daily Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 (2) &amp; 4 mg (15): $3,394.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule Therapy Pack</b> (Lenvima 8 MG Daily Dose Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 (2) mg (10): $3,194.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29044382\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kisplyx (GB);</li>\n      <li>Lenvima (AT, BB, CH, CZ, DE, DK, EE, FR, GB, HK, HR, IE, JP, KR, LT, MY, NL, NO, PH, PL, PT, SE, SG, SK, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Cheng.2017\"></a>Cheng AL, Finn RS, Qin S, et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC) (abstract). <i>J Clin Oncol.</i> 2017;35(suppl; abstr 4001) [Abstract 4001 from ASCO 2017 Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lenvima (lenvatinib) [product monograph]. Mississauga, Ontario, Canada: Eisai Limited; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lenvima (lenvatinib) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <i>Lancet Oncol</i>. 2015;16(15):1473-1482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/26482279/pubmed\" target=\"_blank\" id=\"26482279\">26482279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. <i>N Engl J Med</i>. 2015;372(7):621-630.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenvatinib-drug-information/abstract-text/25671254/pubmed\" target=\"_blank\" id=\"25671254\">25671254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 99962 Version 73.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F27277214\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F49242805\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F27157980\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F27378082\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F27378083\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F27378084\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F27378085\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F27378086\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F27277215\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F27277213\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F27339507\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F27377699\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F27378092\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132642\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F27157982\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50786809\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F27377697\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F27386862\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F27157983\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F27377922\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F27164162\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F27164159\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F27377702\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F27377704\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F27378102\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F27378026\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F27378028\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F27658121\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F29044382\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/99962|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lenvatinib-patient-drug-information\" class=\"drug drug_patient\">Lenvatinib: Patient drug information</a></li></ul></div></div>","javascript":null}